Planning for a Phase III trial is “well underway” at KalVista Pharmaceuticals, Inc. following the company’s announcement of positive data from its Phase II study of an oral drug for treating hereditary angioedema (HAE) attacks. The company sees the drug as being potentially ideal for patients who treat their disease either prophylactically or on-demand.
KalVista Reports Positive Phase II Data For Oral HAE Attack Therapy KVD900
Drug Appears Well Positioned Vs. Approved Therapies
The company sees KVD900 as potentially “ideal” for patients using on-demand and prophylactic therapy, given the existing need to carry backup on-demand medications.
More from R&D
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
More from Scrip
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.